Why Is CORCEPT THERAPEUTICS (CORT) Stock Up Today?
By the Top Tier Newswire AI Desk · July 31, 2026 at 12:02 AM ET · reviewed against 8 wire stories
CORCEPT THERAPEUTICS (CORT) is up +27.29% in the latest session. Our newswire has captured 8 stories on CORT across 7 sources in the last 36 hours, with AI sentiment reading bullish (avg 61/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Corcept Therapeutics (CORT) surged 27.29% to $118.32 in a single session, marking its best day in nearly 16 months. The rally followed the company's second-quarter 2026 earnings report, which showed a 32% revenue increase to $256.1 million and an upward revision of its 2026 revenue guidance to $1.1, $1.2 billion. The stock's sharp rise was also supported by an upgraded price target from H.C. Wainwright and positive analyst coverage highlighting the rapid adoption of its drug Lifyorli and strong performance in existing product lines.
What Happened
Corcept Therapeutics reported Q2 2026 results that exceeded expectations, with revenue growth driven by the successful launch of Lifyorli and continued strength in its established franchises. The company raised its full-year revenue forecast, signaling confidence in its market position and product pipeline. H.C. Wainwright raised its price target to $165, citing the strong performance. The stock's upward momentum was further reinforced by coverage from multiple outlets, including Seeking Alpha and Stocktwits News, which highlighted the stock's 52-week highs and improved guidance. Anika Therapeutics also saw a similar rise, but Corcept Therapeutics remained the focal point of the biotech sector's gains.
What The Data Shows
The stock has risen 23.7% over the last eight sessions, moving from $95.65 to $118.32. Over the past 30 days, insider transactions totaled $26.3 million in sales, with no insider purchases recorded. The company’s fundamentals show a market cap of $10.1 billion, a P/E ratio of 231.2, and a trailing twelve-month revenue increase of 12.2%. Despite the recent gains, the stock remains within its 52-week range of $28.66 to $97.63, indicating a significant breakout.
What To Watch
The company is scheduled to release further updates on the status of relacorilant, which awaits a December 17, 2026 PDUFA decision. Investors should also monitor coverage breadth and any additional analyst upgrades or downgrades in the coming days.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
CORT · Jul 31 session (5-min) · -3.24% vs prior close · updated 8:55 PM ETAI sentiment, last 36h · averaged over 8 stories · 61/100 bullish
The headlines behind the move
Story flow · 8 stories on the wire, last 36h · hover or tap a dot for the headline
11d agoStocktwits NewsBULLISH 68Earnings
These 2 Biotech Stocks Hit New 52-Week Highs Today – And CORT Clocked Its Best Day In Nearly 16 Months
Corcept Therapeutics and Anika Therapeutics received Wall Street support after reporting strong second-quarter results and sharply raising their full-year 2026 outlook.
11d agoMarketChameleonBULLISH 73Earnings
Corcept Therapeutics Ups 2026 Revenue Guidance as Lifyorli Launch Accelerates Growth
July 30, 2026
Corcept Therapeutics reports Q2 results with a 32% revenue jump to $256.1M—driven by the rapid uptake of Lifyorli and robust growth in established franchises. The company boosts its 2026 revenue outlook to $1.1–$1.2B, fueled by expanding product launches and a deep clinical pipeline targeting endocrine, oncology, metabolic, and neurologic disorders.
Filed: 2026-07-29 AccNo: 0001628280-26-050607 Size: 255 KB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
12d agoStockTitanNEUTRAL 50General
Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update | CORT Stock News
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →